MSB 1.03% 98.0¢ mesoblast limited

Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-2

  1. 577 Posts.
    lightbulb Created with Sketch. 4792
    These results are simply amazing. One wonders how the FDA could ignore this latest data (but who knows).

    This is Long-term evidence of survival of children treated with remestemcel-L, through 4 years. Four years !!!

    Overall survival at 2 years was 51% in remestemcel-L treated children, as opposed to just 25-38% if they received best available therapy(BAT)

    In the words of the company ... "These long-term survival outcomes are a key component of the Biologics License Application(BLA) resubmission to the United States Food and Drug Administration (FDA)" So now we know.

    Finally we should see 'daylight' with the FDA. These data speak for themselves.

    Opinion only of course.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
98.0¢
Change
0.010(1.03%)
Mkt cap ! $1.118B
Open High Low Value Volume
96.0¢ 99.0¢ 95.5¢ $5.286M 5.409M

Buyers (Bids)

No. Vol. Price($)
3 91218 98.0¢
 

Sellers (Offers)

Price($) Vol. No.
99.0¢ 63577 4
View Market Depth
Last trade - 16.10pm 27/06/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.